Safety and Efficacy of ZVS101e in Patients With Bietti 's Crystalline Dystrophy

Inclusion Criteria: * 1\. Fully understand the purpose and requirements of this trial, voluntarily participate in the clinical trial, sign the informed consent form, and be able to complete the whole trial processes as required by the protocol; * 2\. Patients with clinical diagnosis of Bietti's crystalline dystrophy (BCD) (age ≥ 18 years) (including the critical value, and the age is based on the time of signing the informed consent form); * 3\. Genetic test confirmed to carry two pathogenic variants of CYP4V2 and carry no pathogenic mutations of other ophthalmic genetic diseases; * 4\. The study eye must meet the following requirements: Best-corrected visual acuity between 2.3 LogMAR and 0.5 LogMAR (including 2.3 LogMAR and 0.5 LogMAR). Exclusion Criteria: * 1\. Subjects with insufficient viable retinal cells, or macular retinal less than 100 μm thick; * 2\. Pre-existing eye conditions in the study eye that the investigator determines could interfere with ocular evaluation, preclude surgery, interfere with interpretation of study endpoints or pose surgical complications; * 3\. The study eye has been treated with the following intraocular procedures: retinal detachment surgery, vitrectomy; * 4\. The study eye has been treated with other drugs within 3 months that could affect the evaluation of the investigational drug (such as ranibizumab, bevacizumab, aflibercept, conbercept); * 5\. Currently taking or may require systemic medications that can cause ocular toxicity, such …